PepGen (PEPG) said Wednesday it has received a new patent from the US Patent and Trademark Office for PGN-EDODM1, its investigational candidate being developed to treat myotonic dystrophy type 1 -- a severe nueromuscular disease.

The therapy candidate utilizes the company's Enhanced Delivery Oligonucleotide platform, the company said.

The new patent will expire in H2 2042, with the possibility of an extension after US Food and Drug Administration approval of PGN-EDODM1, the company said.